ECSP24020925A - Profármaco de derivados de pirrolidona como activador de glucocinasa - Google Patents

Profármaco de derivados de pirrolidona como activador de glucocinasa

Info

Publication number
ECSP24020925A
ECSP24020925A ECSENADI202420925A ECDI202420925A ECSP24020925A EC SP24020925 A ECSP24020925 A EC SP24020925A EC SENADI202420925 A ECSENADI202420925 A EC SENADI202420925A EC DI202420925 A ECDI202420925 A EC DI202420925A EC SP24020925 A ECSP24020925 A EC SP24020925A
Authority
EC
Ecuador
Prior art keywords
glucocinase
prodrug
activator
compound
formula
Prior art date
Application number
ECSENADI202420925A
Other languages
English (en)
Inventor
Guanghua Lv
Li Chen
Jin She
Fuxing Tang
Xiangle Jin
Original Assignee
Hua Medicine Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hua Medicine Shanghai Ltd filed Critical Hua Medicine Shanghai Ltd
Publication of ECSP24020925A publication Critical patent/ECSP24020925A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente divulgación proporciona un compuesto de fórmula (I), o un producto isotópicamente marcado, un enantiómero, un diastereoisómero o una sal farmacéuticamente aceptable del mismo; una composición farmacéutica que comprende un compuesto de fórmula (I); y el uso de un compuesto de fórmula (I) o una composición farmacéutica del mismo en el tratamiento de la diabetes mellitus y síntomas relacionados.
ECSENADI202420925A 2021-09-15 2024-03-15 Profármaco de derivados de pirrolidona como activador de glucocinasa ECSP24020925A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111079620 2021-09-15
CN202211093895 2022-09-08

Publications (1)

Publication Number Publication Date
ECSP24020925A true ECSP24020925A (es) 2024-04-30

Family

ID=83505858

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202420925A ECSP24020925A (es) 2021-09-15 2024-03-15 Profármaco de derivados de pirrolidona como activador de glucocinasa

Country Status (31)

Country Link
US (2) US12054477B2 (es)
EP (2) EP4244221B1 (es)
JP (1) JP7751731B2 (es)
KR (1) KR20240044465A (es)
CN (1) CN117940419A (es)
AR (1) AR127064A1 (es)
AU (1) AU2022346020A1 (es)
CA (1) CA3231566A1 (es)
CL (1) CL2024000738A1 (es)
CO (1) CO2024002748A2 (es)
DK (1) DK4244221T3 (es)
EC (1) ECSP24020925A (es)
ES (1) ES3063045T3 (es)
FI (1) FI4244221T3 (es)
GE (1) GEP20267848B (es)
HR (1) HRP20260241T1 (es)
IL (1) IL311237A (es)
JO (1) JOP20240055A1 (es)
LT (1) LT4244221T (es)
MA (1) MA62175B1 (es)
MD (1) MD4244221T2 (es)
MX (1) MX2024003068A (es)
PE (1) PE20240933A1 (es)
PL (1) PL4244221T3 (es)
PT (1) PT4244221T (es)
RS (1) RS67759B1 (es)
SI (1) SI4244221T1 (es)
SM (1) SMT202600065T1 (es)
TW (1) TW202328107A (es)
WO (1) WO2023040937A1 (es)
ZA (1) ZA202402086B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021243646A1 (en) * 2020-06-04 2021-12-09 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with hepatic impairment
AR132113A1 (es) * 2023-03-13 2025-05-28 Hua Medicine Shanghai Ltd Forma sólida de derivados de pirrolidona como activador de glucoquinasa
IL325046A (en) 2023-06-06 2026-02-01 Hua Medicine Shanghai Ltd Activates glucokinase for cognitive disorders and neurodegenerative diseases
AU2024400384A1 (en) 2023-12-14 2026-07-09 Hua Medicine USA Inc. Pharmaceutical formulation comprising glucokinase activator and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
WO2009126782A1 (en) 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US20120058937A9 (en) * 2008-04-15 2012-03-08 Tsrl, Inc. Prodrugs of Neuraminidase Inhibitors
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772541B2 (en) 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
US9388168B2 (en) * 2012-12-25 2016-07-12 Hua Medicine Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine
HK1252693A1 (zh) 2015-06-30 2019-05-31 Dana Farber Cancer Institute, Inc. Egfr抑制剂及其使用方法
WO2017066705A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
DK3556354T3 (da) 2016-12-15 2025-08-04 Hua Medicine Shanghai Ltd Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf
US11358940B2 (en) 2017-04-20 2022-06-14 The Regents Of The University Of California K-Ras modulators
BR112020024269A2 (pt) * 2018-05-31 2021-02-23 Hua Medicine (Shanghai) Ltd. combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
US10689360B1 (en) 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
US11008303B2 (en) 2019-01-30 2021-05-18 Insilico Medicine Ip Limited TLR 9 inhibitors
WO2022040604A1 (en) 2020-08-21 2022-02-24 BioAge Labs, Inc. Use of dp1 receptor antagonists for the treatment of viral respiratory tract infections and dysregulated immune response in aged and aging patients

Also Published As

Publication number Publication date
PE20240933A1 (es) 2024-04-30
EP4244221B1 (en) 2025-12-10
RS67759B1 (sr) 2026-03-31
HRP20260241T1 (hr) 2026-04-10
MD4244221T2 (ro) 2026-04-30
LT4244221T (lt) 2026-02-25
JP7751731B2 (ja) 2025-10-08
US20230322738A1 (en) 2023-10-12
CA3231566A1 (en) 2023-03-23
EP4244221A1 (en) 2023-09-20
MA62175B1 (fr) 2026-02-27
JP2024533536A (ja) 2024-09-12
PT4244221T (pt) 2026-02-11
KR20240044465A (ko) 2024-04-04
GEP20267848B (en) 2026-01-26
DK4244221T3 (da) 2026-02-23
FI4244221T3 (fi) 2026-02-19
US20240336597A1 (en) 2024-10-10
IL311237A (en) 2024-05-01
EP4714442A2 (en) 2026-03-25
MX2024003068A (es) 2024-03-27
CO2024002748A2 (es) 2024-03-27
CN117940419A (zh) 2024-04-26
AR127064A1 (es) 2023-12-13
EP4714442A3 (en) 2026-06-03
SMT202600065T1 (it) 2026-03-09
ZA202402086B (en) 2024-11-27
SI4244221T1 (sl) 2026-04-30
TW202328107A (zh) 2023-07-16
AU2022346020A1 (en) 2024-03-21
WO2023040937A1 (en) 2023-03-23
PL4244221T3 (pl) 2026-04-20
JOP20240055A1 (ar) 2024-03-14
GEAP202416483A (en) 2024-04-25
US12054477B2 (en) 2024-08-06
ES3063045T3 (en) 2026-04-15
CL2024000738A1 (es) 2024-08-30

Similar Documents

Publication Publication Date Title
CO2024002748A2 (es) Profármaco de derivados de pirrolidona como activador de glucocinasa
CL2024000593A1 (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento...
MX2022007350A (es) Derivados de pirazolilo utiles como agentes anticancerigenos.
AR112284A1 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
UY27518A1 (es) Nuevos derivados de pirrolidina
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
AR060675A1 (es) Derivados de n-(2-tiazolil)-amida como inhibidores de gsk-3,metodo de preparacion, composiciones farmaceuticas que los contienen,y usos terapeuticos.
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
ECSP109934A (es) Compuesto - 946
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CL2008003153A1 (es) Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras.
CL2010001358A1 (es) Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina.
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
UY27666A1 (es) Nuevos derivados de piridina y quinolina
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
CL2008001560A1 (es) Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.